J
Johannes G. Reiter
Researcher at Stanford University
Publications - 41
Citations - 5045
Johannes G. Reiter is an academic researcher from Stanford University. The author has contributed to research in topics: Cancer & Primary tumor. The author has an hindex of 20, co-authored 40 publications receiving 3975 citations. Previous affiliations of Johannes G. Reiter include Institute of Science and Technology Austria & Harvard University.
Papers
More filters
Journal ArticleDOI
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A. Diaz,Luis A. Diaz,Richard Thomas Williams,Jian Wu,Jian Wu,Isaac Kinde,J. Randolph Hecht,Jordan Berlin,Benjamin L. Allen,Ivana Bozic,Johannes G. Reiter,Johannes G. Reiter,Martin A. Nowak,Kenneth W. Kinzler,Kelly S. Oliner,Bert Vogelstein +15 more
TL;DR: Results suggest that the emergence of KRAS mutations is a mediator of acquired resistance to EGFR blockade and that these mutations can be detected in a non-invasive manner, which explains why solid tumours develop resistance to targeted therapies in a highly reproducible fashion.
Journal ArticleDOI
Mutations driving CLL and their evolution in progression and relapse.
Dan A. Landau,Eugen Tausch,Amaro Taylor-Weiner,Chip Stewart,Johannes G. Reiter,Jasmin Bahlo,Sandra Kluth,Ivana Bozic,Michael S. Lawrence,Sebastian Böttcher,Scott L. Carter,Scott L. Carter,Kristian Cibulskis,Daniel Mertens,Daniel Mertens,Carrie Sougnez,Mara Rosenberg,Julian M. Hess,Jennifer Edelmann,Sabrina Kless,Michael Kneba,Matthias Ritgen,A. M. Fink,Kirsten Fischer,Stacey Gabriel,Eric S. Lander,Martin A. Nowak,Hartmut Döhner,Michael Hallek,Michael Hallek,Donna Neuberg,Gad Getz,Gad Getz,Stephan Stilgenbauer,Catherine J. Wu +34 more
TL;DR: Large sequencing data sets of clinically informative samples enable the discovery of novel genes associated with cancer, the network of relationships between the driver events, and their impact on disease relapse and clinical outcome.
Journal ArticleDOI
Evolutionary dynamics of cancer in response to targeted combination therapy
Ivana Bozic,Johannes G. Reiter,Benjamin L. Allen,Benjamin L. Allen,Tibor Antal,Krishnendu Chatterjee,Preya Shah,Yo Sup Moon,Amin Yaqubie,Nicole Kelly,Dung T. Le,Evan J. Lipson,Paul B. Chapman,Luis A. Diaz,Bert Vogelstein,Martin A. Nowak +15 more
TL;DR: It is found that dual therapy results in long-term disease control for most patients, if there are no single mutations that cause cross-resistance to both drugs; in patients with large disease burden, triple therapy is needed.
Journal ArticleDOI
Origins of lymphatic and distant metastases in human colorectal cancer.
Kamila Naxerova,Kamila Naxerova,Johannes G. Reiter,Elena F. Brachtel,Jochen K. Lennerz,Marc van de Wetering,Andrew Rowan,Tianxi Cai,Hans Clevers,Charles Swanton,Charles Swanton,Martin A. Nowak,Stephen J. Elledge,Stephen J. Elledge,Rakesh K. Jain +14 more
TL;DR: Two different lineage relationships between lymphatic and distant metastases exist in colorectal cancer, which provides a mechanistic basis for the TNM staging system and is the rationale for surgical resection of tumor-draining lymph nodes.
Journal ArticleDOI
Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer
Alvin Makohon-Moore,Ming Zhang,Johannes G. Reiter,Ivana Bozic,Benjamin L. Allen,Benjamin L. Allen,Deepanjan Kundu,Krishnendu Chatterjee,Fay Wong,Yuchen Jiao,Zachary A. Kohutek,Jungeui Hong,Marc A. Attiyeh,Breanna Javier,Laura D. Wood,Ralph H. Hruban,Martin A. Nowak,Nickolas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Bert Vogelstein,Christine A. Iacobuzio-Donahue +21 more
TL;DR: The genetic similarity among the founding cells of metastases was higher than that expected for any two cells randomly taken from a normal tissue and has critical and encouraging implications for the success of future targeted therapies in advanced-stage disease.